Targets › CD5
12 programs from 9 companies in 19 trials: 18 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
Lymphoid-specific receptor expressed by all T-cells and in a subset of B-cells known as B1a cells. Plays a role in the regulation of TCR and BCR signaling, thymocyte selection, T-cell effector differentiation and immune tolerance. (UniProt, P06127)
Open in Phaseline: the race on CD5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| March Biosciences | MB-105 CD5-targeted CAR T-cell therapy | CD5 | Phase 2 | Lymphoma, T-Cell | Feb 2028 |
| Essen Biotech | CD5/CD7 CAR-T Chimeric antigen receptor T cells targeting CD5 and CD7 | CD5, CD7 | Phase 1 | T Cell Lymphoma | Dec 2026 |
| Beijing GoBroad Hospital | Autologous CD5 CAR T-cells anti-CD5 CAR-T cell therapy | CD5 | Phase 1 | T-Cell Acute Lymphocytic Leukemia | Dec 2026 |
| Beijing GoBroad Hospital | Newly matched donor-derived CD5 CAR T-cells anti-CD5 CAR-T cell therapy | CD5 | Phase 1 | T-Cell Acute Lymphocytic Leukemia | Dec 2026 |
| Peking University People's Hospital | CD5-targeted CAR-T cells Nanobody-based anti-CD5 CAR-T cell therapy | CD5 | Phase 1 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Dec 2026 |
| Chongqing Precision Biotech | Anti-CD5 CAR NK cells anti-CD5 CAR-NK cell therapy | CD5 | Phase 1 | T-ALL/Lymphoma | Mar 2027 |
| Beijing GoBroad Hospital | umbilical cord blood CD19-BCMA CAR-T cells dual-targeted CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA, CD5, CD7 | Phase 1 | Refractory Lupus Nephritis; T-Cell Non-Hodgkin Lymphoma | Apr 2027 |
| Beijing Biotech | EB-CAR5-NK CD5-targeted allogeneic CAR-NK cells | CD5 | Phase 1 | B2 Thymoma | Jun 2027 |
| Baylor College of Medicine | Allogeneic CD5.CAR/28zeta CAR T cells CD5-directed CAR T cell therapy with 28zeta costimulatory domain | CD5 | Phase 1 | T-cell Acute Lymphoblastic Lymphoma | Jun 2028 |
| Baylor College of Medicine | Autologous CD5.CAR/28zeta CAR T cells CD5-directed CAR T cell therapy with 28zeta costimulatory domain | CD5 | Phase 1 | T-cell Acute Lymphoblastic Lymphoma | Jun 2028 |
| Vittoria Biotherapeutics | Senza5 CART5 CD5-deleted CAR-T cell therapy targeting CD5-positive T cell lymphomas | CD5 | Phase 1 | T Cell Non-Hodgkin Lymphoma | Aug 2028 |
| M.D. Anderson Cancer Center | CAR.5/IL15-transduced CB-NK cells CD5-targeted CAR NK cells engineered with IL-15 | CD5, IL15 | Phase 1 | Hematological Malignancy | Dec 2030 |
T-Cell Acute Lymphocytic Leukemia (6) T-cell Acute Lymphoblastic Lymphoma (2) Refractory Lupus Nephritis (2) T-Cell Non-Hodgkin Lymphoma (2) Hematological Malignancy (1) T Cell Lymphoma (1) T Cell Non-Hodgkin Lymphoma (1) Lymphoma, T-Cell (1) T-ALL/Lymphoma (1) Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) B2 Thymoma (1)
other (8), mixed (2), small molecule (1), protein or peptide (1)
Beijing GoBroad Hospital (3) Baylor College of Medicine (2) M.D. Anderson Cancer Center (1) Essen Biotech (1) Vittoria Biotherapeutics (1) March Biosciences (1) Chongqing Precision Biotech (1) Peking University People's Hospital (1) Beijing Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.